# US 11,026,909 B1 · Therapy for viral infections including the novel corona virus (COVID-19) > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,026,909 B1 - Document ID: US11026909B1 - Status: Granted - Kind: B1 - Application number: 17/132,602 - Filed: 2020-12-23 - Granted: 2021-06-08 - Earliest claimed: 2020-07-02 - Applicants: Nadimpally Satyavarahala Raju; Venkata Satya Suresh Attili; Nadimpally Neha Varma; Steven Jerome Moore; Cullen Thomas Moore - Inventors: Nadimpally Satyavarahala Raju; Venkata Satya Suresh Attili; Nadimpally Neha Varma; Steven Jerome Moore; Cullen Thomas Moore - Web page: https://patentgrep.com/patent/US11026909B1 ## CPC - A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205) - A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals} - A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00) - A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose} - A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer} - A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof - A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam - A61K 33/30: Zinc; Compounds thereof - A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger - A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A method for amelioriation of, or prophylaxis against, a viral infection comprising administering to a patient in need of treatment a therapeutically effective amount of 5 aminolevulinic acid, optionally with at least one of cucumarin nano, zinc, vitamin C and methylene blue, and compositions thereof. Such compositions may be used for the treatment of coronavirus infections, including the SARS-CoV-2 virus, and/or rhinoviruses. ## Claims ### Claim 1 A pharmaceutical composition comprising 5-aminolevulinic acid and at least one of curcumin nano, zinc, vitamin C and methylene blue, or pharmaceutically acceptable salt thereof, each present in therapeutically effective amounts, in an admixture with pharmaceutically acceptable excipient. ### Claim 2 (depends on 1) The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid, curcumin nano, and Vitamin C. ### Claim 3 (depends on 2) The pharmaceutical composition of claim 2 wherein the composition is an oral dosage form. ### Claim 4 (depends on 1) The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid, curcumin nano, Vitamin C, and zinc. ### Claim 5 (depends on 4) The pharmaceutical composition of claim 4 wherein the composition is an oral dosage form. ### Claim 6 (depends on 1) The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid, curcumin nano, and zinc. ### Claim 7 (depends on 6) The pharmaceutical composition of claim 6 wherein the composition is an oral dosage form. ### Claim 8 (depends on 1) The pharmaceutical composition of claim 1 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof. ### Claim 9 (depends on 1) The pharmaceutical composition of claim 1 wherein the therapeutic dose of 5-aminolevulinic acid is 100 mg-1600 mg provided in a single or divided doses of twice daily or thrice daily, the therapeutic dose of curcumin nano is 100 mg-1000 mg provided in a single or divided doses of twice daily or thrice daily, the therapeutic dose of Vitamin C is 80 mg-1000 mg provided in a single or divided doses of twice daily or thrice daily, the therapeutic dose of zinc is 5 mg-150 mg provided in a single or divided doses of twice daily or thrice daily, and the therapeutic dose of methylene blue is 50 mg-250 mg provided in a single or divided doses of twice daily or thrice daily. ### Claim 10 (depends on 1) The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid and methylene blue. ### Claim 11 (depends on 9) The pharmaceutical composition of claim 9 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof. ### Claim 12 (depends on 1) The pharmaceutical composition of claim 1, comprising 5-aminolevulinic acid and zinc. ### Claim 13 (depends on 12) The pharmaceutical composition of claim 12 wherein the composition is an oral dosage form. ### Claim 14 (depends on 12) The pharmaceutical composition of claim 12 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof. ### Claim 15 (depends on 1) The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid, and curcumin nano. ### Claim 16 (depends on 15) The pharmaceutical composition of claim 15 wherein the composition is an oral dosage form. ### Claim 17 (depends on 15) The pharmaceutical composition of claim 15 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof. ### Claim 18 (depends on 1) The pharmaceutical composition of claim 1, comprising 5-aminolevulinic acid and vitamin C. ### Claim 19 (depends on 18) The pharmaceutical composition of claim 18 wherein the composition is an oral dosage form. ### Claim 20 (depends on 18) The pharmaceutical composition of claim 18 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof.